Association between inflammatory bowel disease and chronic liver diseases and related management strategies
10.3969/j.issn.1001-5256.2020.07.002
- VernacularTitle:炎症性肠病与慢性肝脏疾病的关系及其管理策略
- Author:
Jiangbin WANG
1
Author Information
1. Department of Gastroenterology, Bethune Third Hospital/China-Japan Union Hospital of Jilin University, Changchun 130033, China
- Publication Type:Research Article
- Keywords:
inflammatory bowel disease;
liver diseases;
diagnosis;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(7):1444-1449
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is often accompanied by chronic liver diseases in a variety of situations. Due to the overlapping factors in the pathogenesis of IBD and autoimmune liver diseases including primary sclerosing cholangitis (PSC), primary biliary cholangitis, and autoimmune hepatitis, the co-existence of these diseases is not uncommon, among which PSC with IBD has the highest probability of more than 80%. The probability of IBD with chronic hepatitis B virus (HBV)/hepatitis C virus (HCV) infection is associated with local infection rate, and if the screening for HBV/HCV infection is ignored before the application of immunosuppressive agents, there may be a risk of aggravated HBV/HCV infection or HBV reactivation. Long-term treatment with antibiotics, steroids, and immunosuppressants may cause drug-induced liver injury in patients with IBD. Although IBD patients often have weight loss due to the factors including diarrhea and absorption disorders, these patients may have a higher probability of nonalcoholic fatty liver disease than the general population.
